Which medications in the drug class Antineoplastics, mTOr Kinase Inhibitor are used in the treatment of Waldenstrom Macroglobulinemia?

Updated: Feb 01, 2021
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Antineoplastics, mTOr Kinase Inhibitor

These antineoplastic agents have antiproliferative and antiangiogenic properties.

Everolimus (Afinitor, Zortress)

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that is approved by the US Food and Drug Administration for the treatment of renal cell cancer, subependymal giant cell astrocytoma, and advanced neuroendocrine tumors of pancreatic origin. It is a kinase inhibitor that inhibits antigenic and interleukin (IL-2 and IL-5)–stimulated activation and proliferation of T and B lymphocytes. Phase II studies demonstrate activity in relapsed Waldenström macroglobulinemia.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!